Align Capital Partners, a private equity firm with offices in Dallas and Cleveland, has recapitalized Premier Biotech, a provider of point-of-care drugs of abuse testing products and laboratory services for customers across the workplace government and behavioral health end markets.

Premier Biotech was founded in 2009 and shortly after launched the company’s oral fluid testing product OralTox. The company aims to provide cost-effective drug testing at the point of care with results that allow for faster and more informed decision-making. ACP’s investment looks to help drive research and development and support growth with ACP’s operating, technology and sales resources.

“Premier has grown to become a niche leader in the point-of-care drug testing market by developing a differentiated, tech-enabled offering with a clear value proposition for its customers,” comments Rob Langley, ACP managing partner.  “We see the post-COVID normalization of self-testing and oral testing as a tailwind for the industry, and believe the company is poised to benefit with their highly effective and easy-to-use products.”   

Premier Biotech was advised on the transaction by Cascadia Capital and Winthrop & Weinstine, while ACP was advised by McGuire Woods LLP.